Cabot Corporation (CBT): what the price requires

At today's price, Cabot Corporation (CBT) is priced for -3.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CBT

Headline

FieldValue
TickerCBT
CompanyCabot Corporation
Current price$87.59/sh
CompositionReinforcement Materials 63% / Performance Chemicals 34% / Unallocated and other 3%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed7.1%
Operating margin today16.3%
Margin compression implied-9.2pp
Implied growth-3.6%
Multiple paid10x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~4.8pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.04σ
cohort percentile (of 74 peers)16
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.46x5expensive
Earnings1.27x5expensive
Relative1.16x3expensive
Growth1.12x3expensive

Families that justify the price: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=16)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$78.001.12xyesFCF base $0.4B, growth -8% (input: historical growth), terminal g 0.5%, WACC 7.7%, 5yr projection
DCF Exit MultipleGrowth$105.710.83xyesExit EV/EBITDA: 7.0x / 9.0x / 11.0x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$74.961.17xyesP/E 14x (static sector reference · 2026-04), scenarios: 11.8x / 14.0x / 16.2x (bear / base = reference held flat / bull), EV/EBITDA 8x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$59.021.48xyesBV/sh $30.04, ROE (TTM) 18.2%, ke 9.3%
Two-Stage Excess ReturnAsset$81.701.07xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$46.471.88xyesRev $3.6B, growth -8% (input: historical growth; tapered), Terminal P/S: 1.1x / 1.3x / 1.5x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$106.410.82xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.57B × (1−21%) / WACC 7.7% → EPV (no growth)
Residual IncomeAsset$81.021.08xyesBV $30.04 + 5yr PV of (ROE (TTM) 18.2% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$59.851.46xyes√(22.5 × EPS $5.30 × BVPS $30.04) — Graham's conservative floor
EV/EBITDA RelativeRelative$75.711.16xyesEBITDA $0.60B × sector EV/EBITDA 8.0x
FCF YieldEarnings$72.761.20xyesFCF $432.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$69.241.27xyesSBC-adj FCF $0.41B (FCF $0.43B − SBC $0.02B) capitalized at Kₑ
Ben Graham FormulaEarnings$4.4419.73xyesEPS $5.30 × (8.5 + 2×-5.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$16.355.36xyesBV $30.04 × (ROIC 4.2% / WACC 7.7%)
P/Sales SectorRelative$102.730.85xyesRevenue $3.58B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$57.301.53xyesEPS $5.30 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.1b
Net debt / NOPAT (after-tax)2.32x
Net debt / operating income (pre-tax)1.83x
Interest coverage7.9x
Share count CAGR (buyback)-2.2%
Burning cashno

Bullet Takeaways

Bull Case

Look at what the price assumes versus what the business is doing, and Cabot starts to look mispriced in the buyer's favor. At today's level the market embeds essentially flat to slightly declining operating profit, which is a low bar for a company that earns a 15.7% operating margin and a return on equity around 18%. The price is not paying for growth; it is paying for the business not to deteriorate. That is a defensive starting point, and it leaves the upside in the parts of Cabot the market is treating as an afterthought.

The clearest of those parts is battery materials. Cabot makes the conductive additives that go into lithium-ion cells, and the 10-K is direct that demand for them "is largely driven by the trend in electrification of vehicles and the increase in energy storage systems." That business grew revenue 43% year over year in the most recent quarter, and while it is still small, it is the kind of secular growth engine that a cyclical-materials company rarely has bolted onto a stable core. As it scales toward a more meaningful share of profit, it changes the character of the company from pure cyclical to cyclical-plus-growth, and the current multiple gives no credit for that shift.

The core itself is more durable than its current softness suggests, and the capital model is shareholder-friendly. Carbon black is a consolidated, capital-intensive industry where Cabot is a global leader, and its supply contracts use feedstock indices to pass through raw-material cost changes, which protects margins through input swings. The company generates real free cash flow, has been shrinking its share count about 2% a year, and pays a steady dividend. The valuation methods that price the earnings, relative multiples and cash flow, support or exceed the current price; only the asset-based lenses read it as expensive, which understates a business whose value is its franchise and technology rather than its book assets.

Bear Case

The capital-allocation question is the right lens on Cabot's bear case: the company is pouring investment into a small, fast-growing battery business while its large core grinds through a downturn, and the math has to work on both ends at once. The core is Reinforcement Materials, and it is genuinely weak, hit by lower tire imports, pricing pressure, and underutilized capacity in the Americas and Europe. Cabot itself ties that segment's fate to the auto cycle, noting demand is "largely driven by the growth in vehicle production" and tire replacement. When the cash-generative core is shrinking, every dollar directed to battery-materials capacity is a dollar not cushioning the segment that actually pays the bills, and the bet is that battery materials scales before the core's weakness drags the whole company.

The cyclicality is the structural truth the flat-looking valuation obscures. Specialty materials earn peak margins when capacity is tight and trough margins when it is loose, and Cabot's pricing power is, in its own words, "largely influenced by competitive and economic" conditions it does not control. The pass-through feedstock contracts help, but the filing concedes the indices "may not precisely track our actual costs," which means margin can be squeezed in the gap. Today's 15.7% operating margin is closer to a mid-cycle-to-peak figure than a trough one, and the earnings guidance confirms the direction: fiscal 2026 adjusted EPS of $6.00 to $6.50 is a step down from $7.25 the prior year. A price that embeds flat profit is vulnerable if the cycle has further to fall.

The balance sheet limits the margin for error. Cabot carries net debt of about $1.08 billion, roughly 1.9 times operating income, with interest covered around 7.5 times. That is manageable in a normal year, but it is leverage entering a downturn, and it competes for cash with both the dividend and the battery-materials build-out. Battery materials is expected to contribute only about $40 million of EBITDA in fiscal 2026, a fraction of the company total, so the growth story cannot yet offset a weak core. If tire demand stays soft while the company keeps funding growth capex on a levered balance sheet, the bear case is simply that the cyclical core sets the near-term earnings and the cycle is not Cabot's to time.

Valuation

The bet in Cabot's price is modest, which is the first thing to register. At today's level the market pays about 10 times company-wide operating income, inverting to a requirement of roughly flat, even slightly negative, operating-profit growth over the next several years. Cabot runs a 15.7% operating margin today, so the price is asking the business not to deteriorate rather than to expand. For a cyclical-materials company, that is a low expectations bar, and it reflects the market discounting the carbon-black downturn rather than doubting the franchise.

The methods divide along the asset-versus-earnings line. The asset-value lenses read the stock as expensive, which is the expected result for a specialty-materials business whose value is its technology and market position rather than its book assets; book value near $30 per share understates the earnings power. The relative-multiple and cash-flow methods, which price the earnings, support or exceed the current price. The pattern is a name justified by what it earns, not by what it owns, and the asset-based skepticism is more an artifact of the accounting than a verdict on the business. The cyclicality is the caveat: the earnings those methods capitalize are mid-cycle-to-elevated, so a deeper downturn would lower the base they rest on.

Solvency frames the downside. Net debt of about $1.08 billion against trailing operating income puts leverage near 1.9 times, with interest covered about 7.5 times, which is serviceable but is real leverage carried into a soft patch. Liquid assets of roughly $252 million are modest, so the company depends on its cash generation holding up. The cohort comparison is the useful frame: Cabot sits among specialty-chemical peers whose earnings are similarly cycle-dependent, and its multiple is not stretched relative to that group. The decisive variable for the buyer is the carbon-black cycle: the price is defensible at mid-cycle earnings, and the battery-materials growth is upside the multiple does not pay for, but a further leg down in tire demand is the scenario the flat-profit assumption does not protect against.

Catalysts

The two halves of Cabot are moving in opposite directions, and the latest quarter showed it clearly. In the second fiscal quarter, the company reported adjusted earnings per share of $1.61, ahead of expectations near $1.46, on revenue of $904 million. The driver of the beat was battery materials, where revenue grew 43% year over year, while the core Reinforcement Materials segment continued to face weak demand from lower tire imports, pricing pressure, and underutilized capacity, especially in the Americas and Europe.

Guidance frames the year as one of digestion rather than growth. Cabot reaffirmed fiscal 2026 adjusted EPS guidance of $6.00 to $6.50, below the $7.25 reported for fiscal 2025, and indicated battery materials should generate roughly $40 million of EBITDA for the year. The forward watch items are the trajectory of tire and carbon-black demand, which sets the near-term earnings, the pace at which battery materials scales toward a meaningful share of profit, and the company's continued restructuring actions. The first is the cyclical question, the second is the secular one, and how they net out decides whether the flat-profit assumption in the price proves conservative or generous.

Peer Cohorts (Per Segment, With Filing Citations)

Reinforcement Materials (reported)

Performance Chemicals (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q2 FY2026 earnings release · Q2 FY2026 earnings call

View the full interactive CBT report on boothcheck